目的:对比研究头孢拉宗等9种抗菌药物对产超广谱β-内酰胺酶(ESBLs)大肠埃希菌以及肺炎克雷伯菌的体外抗菌活性。方法:采用琼脂平板二倍稀释法测定头孢拉宗等9种抗菌药物对临床分离的产ESBLs大肠埃希菌115株、肺炎克雷伯菌30株的最低抑菌浓度(MIC)。结果:产ESBLs大肠埃希菌和肺炎克雷伯菌对亚胺培南/西司他丁(100%和96.7%)、美罗培南的敏感率最高(100%和96.7%),对头孢拉宗(98.3%和93.3%)、头孢美唑(93.0%和96.7%)和阿米卡星(95.7%和96.7%)的敏感率较高,对哌拉西林/他唑巴坦(92.1%和60.0%)、头孢他啶(62.6%和73.3%)比较敏感,但对头孢噻肟(3.5%和0)、头孢哌酮/舒巴坦(43.5%和36.7%)的耐药率很高。结论:头孢拉宗对产ESBLs的大肠埃希菌和肺炎克雷伯菌均有很强的体外抗菌活性。 OBJECTIVE: To compare the antibacterial activity of nine antimicrobial agents such as cefradrazone against ESBLs-producing Escherichia coli and Klebsiella pneumoniae in vitro. Methods: The minimum inhibitory concentration (MIC) of 9 strains of antibacterials such as Cefradrazone against 115 strains of ESBLs-producing Escherichia coli and 30 strains of Klebsiella pneumoniae were determined by agar plate double dilution method. Results: The ESBLs - producing Escherichia coli and Klebsiella pneumoniae showed the highest sensitivity (100% and 96.7%) to imipenem / cilastatin (100% and 96.7%) and the highest to meropenem (98.3% and 93.3%). Cefmetazole (93.0% and 96.7%) and amikacin (95.7% and 96.7%) had a higher sensitivity rate to piperacillin / tazobactam (92.1% and 60.0% %) And ceftazidime (62.6% and 73.3%). However, cefotaxime (3.5% and 0) and cefoperazone / sulbactam (43.5% and 36.7%) were highly resistant to ceftazidime. Conclusion: Cefradine has strong antibacterial activity in vitro against Escherichia coli and Klebsiella pneumoniae producing ESBLs.